April 29 (Reuters) - Teva Pharmaceutical Industries

beat Wall Street estimates for first-quarter profit on

Wednesday, helped by sales of its branded medicines.

Israel-based Teva, the world's largest generics drugmaker,

earned adjusted profit of 53 cents per share, compared with

analysts' estimate of 48 cents per share, according to data

compiled by LSEG.